GlassScriptPhysician profile
Fitore Vula
NPI 1164927497
$8,710.21
in general payments reported to CMS, 2019-2025
31 companies · $3,115 in 2025
The $3,115 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $783 · 2022: $252 · 2023: $1,844 · 2024: $2,716 · 2025: $3,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,566 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,565.52 |
| Education | $110.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,824.27 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $963.87 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $667.32 | 2023-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $666.05 | 2021-2025 | Livdelzi, Epclusa, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $595.52 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $386.64 | 2021-2025 | Entyvio, Gattex |
| Celgene Corporation | $383.98 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $336.26 | 2021-2025 | Stelara, Tremfya |
| Genzyme Corporation | $323.48 | 2024-2025 | |
| Pfizer INC. | $248.78 | 2025 | |
| Ardelyx, INC. | $216.63 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $215.60 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $215.08 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $201.98 | 2024 | Resolution 360 Clip, Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $200.81 | 2024-2025 | Dupixent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $176.02 | 2024-2025 | Sucraid, Sucraid |
| Exact Sciences Corporation | $153.19 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $145.24 | 2025 | Wegovy |
| Enterra Medical, INC. | $138.42 | 2024 | |
| Medtronic, INC. | $128.25 | 2021 | |
| Mallinckrodt Hospital Products INC. | $107.75 | 2023 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $86.75 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $85.45 | 2021-2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $54.76 | 2025 | Vowst, Zenpep |
| Ferring Pharmaceuticals INC. | $46.20 | 2024 | Rebyota |
| Alnylam Pharmaceuticals INC. | $25.97 | 2025 | Givlaari |
| Intercept Pharmaceuticals, INC. | $24.57 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.52 | 2024 | Cyltezo |
| Echosens North America, INC. | $24.35 | 2024 | Fibroscan |
| Digestive Care, INC. | $21.38 | 2025 | Pertzye |
| Celltrion USA INC. | $21.12 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fitore Vula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.